Topic:

R&D

Latest Headlines

Latest Headlines

Adaptimmune's novel cancer treatment posts promising early results

Adaptimmune's pioneering approach to cancer immunotherapy has charted some impressive results in a small study. And while the biotech is quick to point out that it's early days yet, the data underscore the potential of a therapy that has convinced GlaxoSmithKline to bet up to $350 million on its future.

Stanford using ultrasound to power wireless 'smart chip' implant

Stanford seems to have found a niche in tiny wireless implants. In the latest development, the university announced that it is developing methods of beaming ultrasound to power implanted "smart chips" for the treatment of conditions like Parkinson's disease.

Moderna teams up with Karolinska to flesh out its mRNA promise

Well-funded biotech Moderna Therapeutics has inked a long-term deal with Sweden's Karolinska Institutet to spotlight new applications for the company's messenger RNA technology.

Agilent axes 300 employees to focus on applied markets and diagnostics businesses

Agilent Technologies is closing its nuclear magnetic resonance business, as the downsizing of its research products division continues. The move is expected to cost 300 jobs over the next 12 months in Santa Clara, CA, and Yarnton, England. 

AstraZeneca deepens its Cambridge ties with hopes for Alzheimer's and cancer

AstraZeneca, two years away from a big relocation to Cambridge, U.K., is broadening its relationship with the local university, signing a slew of new agreements that will bolster its R&D efforts in neuroscience and oncology.

Meet some of the revolutionaries in biotech R&D

It's become a matter of commonly accepted faith in the biopharma biz that it takes more than $1 billion and 10 years to develop a new drug. Industry associations like to cite that factoid as a reason for the big prices we're seeing on new therapies, often while prodding the FDA for faster action. 

Forward Pharma pulls off a $221M IPO with eyes on unseating Biogen

Danish drug developer Forward Pharma came through with one of the year's biggest biotech IPOs, raising $221 million to support its plot to battle Biogen Idec in the blockbuster multiple sclerosis market.

Stealthy, DNA-based 'nano-cocoons' deliver cancer-killing payloads

Researchers at NC State University and the University of North Carolina have developed a DNA-based delivery vehicle capable of acting as a Trojan horse in cancer cells. Using DNA as a cage instead of synthetic materials makes the vehicle less toxic to healthy cells and allows for the attachment of precise targeting mechanisms.

Stem cell-derived beta cells deliver insulin in response to blood sugar levels

The self-regulation of insulin delivery is a long-sought goal in the field, spurring the development of closed-loop systems and an artificial pancreas for diabetics. But some researchers are aiming smaller, looking at a way to create stem cells en masse that can produce insulin in response to blood sugar levels.

Astellas dives into gene therapy with a Harvard expert in tow

Japan's Astellas Pharma is the latest big drugmaker allured by the promise of gene therapy, mounting an R&D effort that could lead to a new treatment for an inherited eye disease.